triazoles has been researched along with Huntington Disease in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, M; Casale, MS; Fraenkel, E; Kedaigle, AJ; Lim, RG; Reidling, JC; Stocksdale, JT; Thompson, LM; Wassie, B; Wu, J | 1 |
| Cabanas, M; Cho, YH; Garret, M; Jeantet, Y; Pistono, C; Puygrenier, L; Rakesh, D | 1 |
| Alberch, J; Canas, PM; Cunha, RA; Delgado-García, JM; Gruart, A; Pérez-Navarro, E; Pliassova, A; Saavedra, A; Tyebji, S | 1 |
| Bonaventura, J; Brugarolas, M; Casadó, V; Cellai, L; Chang, CP; Chern, Y; Cortés, A; Dettori, I; Ferré, S; Guitart, X; Narayanan, M; Orrú, M; Pedata, F; Rea, W | 1 |
| Bizzoco, E; Cipriani, S; Gianfriddo, M; Melani, A; Pedata, F; Vannucchi, MG | 1 |
| Armida, M; Domenici, MR; Ferrante, A; Ferretti, R; Martire, A; Pézzola, A; Popoli, P; Potenza, RL | 1 |
| Al-Ramahi, I; Berman, AE; Botas, J; de Haro, M; DeGiacomo, F; Ellerby, LM; Gafni, J; Holcomb, J; Hughes, RE; Kim, E; Miller, JP; Mooney, SD; Sanhueza, M; Torcassi, C; Yates, BE | 1 |
| Corsi, C; Gianfriddo, M; Melani, A; Pedata, F; Pèzzola, A; Popoli, P; Reggio, R | 1 |
| Gianfriddo, M; Giovannini, MG; Melani, A; Pedata, F; Turchi, D | 1 |
| Abbracchio, MP; Bates, G; Borea, PA; Camurri, A; Cattaneo, E; Tarditi, A; Varani, K; Woodman, B | 1 |
| Calamandrei, G; Fusco, FR; March, ZD; Pezzola, A; Popoli, P; Scattoni, ML; Valanzano, A | 1 |
| Borioni, A; Calamandrei, G; Domenici, MR; Lastoria, G; Martire, A; Popoli, P; Potenza, RL; Scattoni, ML; Venerosi, A | 1 |
| Domenici, MR; Falchi, M; Frank, C; Malchiodi-Albedi, F; Massotti, M; Pèzzola, A; Pintor, A; Popoli, P; Quarta, D; Reggio, R; Scarchilli, L; Tebano, MT | 1 |
13 other study(ies) available for triazoles and Huntington Disease
| Article | Year |
|---|---|
Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Topics: Acetylation; Animals; Azepines; Behavior Rating Scale; Behavioral Symptoms; Cerebral Cortex; Chromatin Immunoprecipitation Sequencing; Corpus Striatum; Disease Models, Animal; Energy Metabolism; Epigenesis, Genetic; Gene Expression Regulation; Gene Ontology; Histones; Huntingtin Protein; Huntington Disease; Male; Mice; Mice, Transgenic; Motor Activity; Protein Biosynthesis; RNA-Seq; Signal Transduction; Triazoles | 2020 |
Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.
Topics: Animals; Azepines; Cognitive Dysfunction; Disease Models, Animal; Female; Huntington Disease; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Orexin Receptor Antagonists; Orexins; Sleep Disorders, Circadian Rhythm; Triazoles | 2019 |
Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benzazepines; Cognition Disorders; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine Antagonists; Hippocampus; Huntington Disease; Long-Term Potentiation; Male; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Motor Activity; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D1; Triazoles | 2015 |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Biomarkers; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Locomotion; Nucleoside Transport Proteins; Prefrontal Cortex; Psychomotor Disorders; Purines; Rats; Rats, Transgenic; Receptor, Adenosine A2A; Triazines; Triazoles; Trinucleotide Repeat Expansion; Tritium | 2016 |
Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Cytoprotection; Disease Models, Animal; Enzyme Activation; Huntington Disease; Interneurons; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Nitrergic Neurons; Nitric Oxide; Nitric Oxide Synthase Type I; Pyrimidines; Receptor, Adenosine A2A; Triazoles; Up-Regulation | 2008 |
Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Corpus Striatum; Disease Models, Animal; Female; Huntington Disease; In Vitro Techniques; Male; Mice; Mice, Transgenic; N-Methylaspartate; Neuronal Plasticity; Neurotoxins; Pyrimidines; Receptor, Adenosine A2A; Receptor, trkB; Receptors, N-Methyl-D-Aspartate; Triazoles | 2010 |
A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drosophila melanogaster; Farnesyltranstransferase; Genome, Human; HEK293 Cells; Humans; Huntingtin Protein; Huntington Disease; Metabolic Networks and Pathways; Mice; Mitochondria; Mutation; Nerve Tissue Proteins; Neurons; Pyrimidines; ras Proteins; RNA Interference; Signal Transduction; Triazoles | 2012 |
Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Extracellular Space; Glutamic Acid; Huntington Disease; Male; Microdialysis; Models, Animal; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinolinic Acid; Rats; Rats, Wistar; Receptor, Adenosine A2A; Time Factors; Triazoles | 2003 |
Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Extracellular Fluid; Glutamic Acid; Huntington Disease; Male; Mice; Mice, Inbred CBA; Mice, Transgenic; Mitogen-Activated Protein Kinases; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2004 |
Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease.
Topics: Adenylyl Cyclases; Animals; Basal Ganglia; Cyclic AMP; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; Receptors, Adenosine A2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Triazines; Triazoles | 2006 |
Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Behavior, Animal; Behavioral Symptoms; Corpus Striatum; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Huntington Disease; Male; Maze Learning; Neuroprotective Agents; Pyrimidines; Quinolinic Acid; Rats; Rats, Wistar; Receptor, Adenosine A2A; Time Factors; Triazoles | 2007 |
Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Brain; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Glutamic Acid; Huntington Disease; Learning Disabilities; Maze Learning; Mental Disorders; Mice; Mice, Transgenic; Motor Activity; Neuroprotective Agents; Organ Culture Techniques; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2007 |
Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
Topics: Animals; Behavior, Animal; Calcium; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Electroencephalography; Excitatory Amino Acid Antagonists; Gliosis; Glutamic Acid; Hippocampus; Huntington Disease; Long-Term Potentiation; Male; Maze Learning; Motor Activity; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Presynaptic Terminals; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinolinic Acid; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Triazoles | 2002 |